RNS Number : 5163V
MaxCyte, Inc.
15 April 2021
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notice of Full Year Results
Gaithersburg, Maryland - 15 April 2021 : MaxCyte (LSE: MXCT, MXCL, MXCN), a leading provider of cell-engineering platform technologies for next generation cell-based therapies, will be announcing its financial results for the year ended 31 December 2020 on Tuesday, 20 April 2021.
Doug Doerfler, Chief Executive Officer, and Amanda Murphy, Chief Financial Officer, will host a conference call for analysts at 14.00pm BST the day of the announcement. The presentation will be available on the Investors section of MaxCyte's website on the day of the meeting at https://investors.maxcyte.com/news-events/documents-presentations .
###
For further information please contact:
|
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer
|
+1 301 944 1660
|
|
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden
|
+44 (0)20 7886 2500
|
|
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith
|
+44 (0)20 7260 1000
|
|
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison / Samira Essebiyea
Corporate Broking
Nick Adams
|
+44 (0) 20 7710 7600
|
|
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott / Chris Welsh
|
+44 (0)203 709 5700
maxcyte@consilium-comms.com
|
About MaxCyte
MaxCyte is a leading provider of cell-engineering platform technologies that are driving the next‐generation of cell-based therapies and making a meaningful difference for patients. The Company's technology is employed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte has granted 12 strategic platform licences to leading cell-based therapy developers. Through 2020, MaxCyte has granted licenses for more than 140 cell therapy programs, with over 100 licensed for clinical use. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, U.S. For more information, visit www.maxcyte.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the
United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the
London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
NORUSORRANUSAUR
